Loading...
Loading...
AXLA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 16.8M |
| Operating I/L | -20.9M |
| Other Income/Expense | -2.1M |
| Interest Income | 0.3M |
| Pretax | -23.0M |
| Income Tax Expense | 1.3M |
| Net Income/Loss | -24.3M |
Axcella Health Inc. is a clinical stage biotechnology company focused on developing endogenous metabolic modulator compositions to treat complex diseases and enhance health. The company's lead product candidates, AXA1665 and AXA1125, are in Phase 2 clinical trials for reducing the risk of hepatic encephalopathy recurrence and treating non-alcoholic steatohepatitis and Long COVID therapy, respectively. By leveraging its innovative product candidates, Axcella Health Inc. aims to generate revenue through the successful development and commercialization of therapies for these conditions.
